Rather than a one-size-fits-all blood test that looks for a single pathology, NeuroDex is commercializing a novel scientific approach, based on the study of extracellular vesicles – that can decipher “mixed pathology” in dementia and lead to a more personalized treatment plan. The Challenge Whenever we write about a company in the Alzheimer’s Moonshot we…
Press Release NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research Natick, Massachusetts (November 6, 2024) – NeuroDex Inc. (“NeuroDex” or the “Company”) proudly announces its selection as a recipient of the Target ALS Biomarker Consortia Grant. This significant funding will bolster NeuroDex’s efforts to pioneer novel blood-based biomarkers, aiming to…
Amidst the complexity of the human body lies the key to understanding various diseases and their treatments: biomarkers. These biological indicators can reveal the state of health or the progression of a disease, making their discovery crucial in medical research. Biomarker discovery services combine cutting-edge science with an understanding of disease mechanisms to identify these…
We are thrilled to announce that Dr. Erez Eitan, NeuroDex’s chief scientific officer (CSO), will participate in the upcoming Alzheimer’s Association International Conference (AAIC) 2024. This prestigious event, taking place from July 28 to August 1 in Philadelphia, USA, will bring together leading scientists, researchers, and healthcare professionals from around the globe to discuss the…
Imagine a future where the onset of Alzheimer’s or Parkinson’s disease could be predicted and effectively treated before symptoms even appear. Neurodegenerative diseases have long remained shrouded in a veil of uncertainty, with definitive diagnoses often coming too late to alter their devastating trajectories. Biomarkers are the beacons of hope in this landscape, potentially revolutionizing…
Several biotech and pharmaceutical companies are actively involved in researching and developing drugs for Parkinson’s disease. Parkinson’s disease is a neurodegenerative disorder that primarily affects movement. Efforts in this area range from developing therapies for managing symptoms to those targeting the disease’s underlying causes. Here are some notable companies and their approaches: ACADIA Pharmaceuticals: ACADIA…
Scientists have successfully created 3D-printed brain tissue that closely mimics the behavior of natural brain tissue. This development holds great promise for advancing research in neurological and neurodevelopment disorders. The novel 3D-printing technique utilizes a horizontal layering method and a softer bio-ink, enabling the interconnection and formation of networks resembling those found in human brain…
Showcasing Pioneering Diagnostic Technologies We proudly announce that Neurodex will play a significant role at the forthcoming Bio-Neuroscience Conference, highlighting our innovative diagnostic technologies for neurodegenerative diseases. Oded Biran, our distinguished SEO, will present our leading-edge work in developing blood-based biomarkers and leveraging cell-specific extracellular vesicles (exosomes) for precise diagnostics. About Our Innovations Neurodex is…
Introduction: The global Neurodegenerative Disease Market is on the cusp of significant expansion, driven by the rising prevalence of neurodegenerative diseases such as Parkinson’s, multiple sclerosis, and Alzheimer’s disease. According to a recent study by MarketDigits, the market is projected to reach USD 69.8 billion by 2030, growing at a robust CAGR of 6.2% during…
Introduction Leqembi® Arrives in China for Alzheimer’s Care Eisai, in partnership with BioArctic AB, has announced China’s approval of Leqembi® (乐意保), a groundbreaking treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease. Following its success in the United States and Japan, this approval marks a significant stride in global healthcare. Understanding Alzheimer’s and…